InspireMD (NYSEAMERICAN:NSPR) is scheduled to release its Q3 earnings data before the market opens on Tuesday, November 12th. Analysts expect InspireMD to post earnings of ($1.35) per share for the quarter.
NYSEAMERICAN NSPR opened at $1.22 on Friday. InspireMD has a 12 month low of $1.11 and a 12 month high of $12.00. The firm has a 50 day moving average of $2.42.
Several equities research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of InspireMD in a report on Monday, August 19th. Zacks Investment Research raised InspireMD from a “sell” rating to a “hold” rating in a report on Thursday, October 17th.
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.
Featured Article: The role of implied volatility with call option volume
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.